Cargando…

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study

OBJECTIVE: To describe the real‐world treatment persistence (defined as the continuation of medication for the prescribed treatment duration), demographics and clinical characteristics, and treatment patterns for patients prescribed erenumab for migraine prevention in Canada. BACKGROUND: The effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Gladstone, Jonathan, Chhibber, Sameer, Minhas, Jagdeep, Neish, Calum S., Power, G. Sarah, Lan, Zhiyi, Rochdi, Driss, Lanthier‐Martel, Jessica, Bastien, Natacha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298790/
https://www.ncbi.nlm.nih.gov/pubmed/34807454
http://dx.doi.org/10.1111/head.14218
_version_ 1784750791788068864
author Gladstone, Jonathan
Chhibber, Sameer
Minhas, Jagdeep
Neish, Calum S.
Power, G. Sarah
Lan, Zhiyi
Rochdi, Driss
Lanthier‐Martel, Jessica
Bastien, Natacha
author_facet Gladstone, Jonathan
Chhibber, Sameer
Minhas, Jagdeep
Neish, Calum S.
Power, G. Sarah
Lan, Zhiyi
Rochdi, Driss
Lanthier‐Martel, Jessica
Bastien, Natacha
author_sort Gladstone, Jonathan
collection PubMed
description OBJECTIVE: To describe the real‐world treatment persistence (defined as the continuation of medication for the prescribed treatment duration), demographics and clinical characteristics, and treatment patterns for patients prescribed erenumab for migraine prevention in Canada. BACKGROUND: The effectiveness of prophylactic migraine treatments is often undermined by poor treatment persistence. In clinical trials, erenumab has demonstrated efficacy and tolerability as a preventive treatment, but less is known about the longer term treatment persistence with erenumab. METHODS: This is a real‐world retrospective cohort study where a descriptive analysis of secondary patient data was conducted. Enrollment and prescription data were extracted from a patient support program for a cohort of patients prescribed erenumab in Canada between September 2018 and December 2019 and analyzed for persistence, baseline demographics, clinical characteristics, and treatment patterns. Descriptive analyses and unadjusted Kaplan–Meier (KM) curves were used to summarize the persistence and dose escalation/de‐escalation at different timepoints. RESULTS: Data were analyzed for 14,282 patients. Median patient age was 47 years, 11,852 (83.0%) of patients were female, and 9443 (66.1%) had chronic migraine at treatment initiation. Based on KM methods, 71.0% of patients overall were persistent to erenumab 360 days after treatment initiation. Within 360 days of treatment initiation, it is estimated that 59.3% (KM‐derived) of patients who initiated erenumab at 70 mg escalated to 140 mg, and 4.4% (KM‐derived) of patients who initiated at 140 mg de‐escalated to 70 mg. CONCLUSIONS: The majority of patients prescribed erenumab remained persistent for at least a year after treatment initiation, and most patients initiated or escalated to a 140 mg dose. These results suggest that erenumab is well tolerated, and its uptake as a new class of prophylactic treatment for migraine in real‐world clinical practice is not likely to be undermined by poor persistence when coverage for erenumab is easily available.
format Online
Article
Text
id pubmed-9298790
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92987902022-07-21 Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study Gladstone, Jonathan Chhibber, Sameer Minhas, Jagdeep Neish, Calum S. Power, G. Sarah Lan, Zhiyi Rochdi, Driss Lanthier‐Martel, Jessica Bastien, Natacha Headache Research Submissions OBJECTIVE: To describe the real‐world treatment persistence (defined as the continuation of medication for the prescribed treatment duration), demographics and clinical characteristics, and treatment patterns for patients prescribed erenumab for migraine prevention in Canada. BACKGROUND: The effectiveness of prophylactic migraine treatments is often undermined by poor treatment persistence. In clinical trials, erenumab has demonstrated efficacy and tolerability as a preventive treatment, but less is known about the longer term treatment persistence with erenumab. METHODS: This is a real‐world retrospective cohort study where a descriptive analysis of secondary patient data was conducted. Enrollment and prescription data were extracted from a patient support program for a cohort of patients prescribed erenumab in Canada between September 2018 and December 2019 and analyzed for persistence, baseline demographics, clinical characteristics, and treatment patterns. Descriptive analyses and unadjusted Kaplan–Meier (KM) curves were used to summarize the persistence and dose escalation/de‐escalation at different timepoints. RESULTS: Data were analyzed for 14,282 patients. Median patient age was 47 years, 11,852 (83.0%) of patients were female, and 9443 (66.1%) had chronic migraine at treatment initiation. Based on KM methods, 71.0% of patients overall were persistent to erenumab 360 days after treatment initiation. Within 360 days of treatment initiation, it is estimated that 59.3% (KM‐derived) of patients who initiated erenumab at 70 mg escalated to 140 mg, and 4.4% (KM‐derived) of patients who initiated at 140 mg de‐escalated to 70 mg. CONCLUSIONS: The majority of patients prescribed erenumab remained persistent for at least a year after treatment initiation, and most patients initiated or escalated to a 140 mg dose. These results suggest that erenumab is well tolerated, and its uptake as a new class of prophylactic treatment for migraine in real‐world clinical practice is not likely to be undermined by poor persistence when coverage for erenumab is easily available. John Wiley and Sons Inc. 2021-11-22 2022-01 /pmc/articles/PMC9298790/ /pubmed/34807454 http://dx.doi.org/10.1111/head.14218 Text en © 2021 Novartis Pharmaceuticals Canada Inc. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC on behalf of American Headache Society https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Submissions
Gladstone, Jonathan
Chhibber, Sameer
Minhas, Jagdeep
Neish, Calum S.
Power, G. Sarah
Lan, Zhiyi
Rochdi, Driss
Lanthier‐Martel, Jessica
Bastien, Natacha
Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
title Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
title_full Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
title_fullStr Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
title_full_unstemmed Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
title_short Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
title_sort real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: retrospective real‐world study
topic Research Submissions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298790/
https://www.ncbi.nlm.nih.gov/pubmed/34807454
http://dx.doi.org/10.1111/head.14218
work_keys_str_mv AT gladstonejonathan realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy
AT chhibbersameer realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy
AT minhasjagdeep realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy
AT neishcalums realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy
AT powergsarah realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy
AT lanzhiyi realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy
AT rochdidriss realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy
AT lanthiermarteljessica realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy
AT bastiennatacha realworldpersistenceoferenumabforpreventivetreatmentofchronicandepisodicmigraineretrospectiverealworldstudy